[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-skin-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-skin-neoplasm":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100568010",false,"NCT06675643","Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App","Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity: A Feasibility Study of the Vigilant App (Vigilant-2)","Inclusion Criteria:\n\n* Any skin cancer\u002Fmelanoma patient starting dual \\[ipilimumab\u002Fnivolumab (IPI\u002FNIVO)\\] immune checkpoint inhibitor (ICI) therapy\n\nExclusion Criteria:\n\n* Does not meet inclusion criteria","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary data on the potential clinical benefit to remote monitoring of adverse events.",[23,24],"Malignant Skin Neoplasm","Melanoma","RECRUITING","2026-02-06",{"date":28,"type":29},"2026-02-10","ACTUAL",{"date":31,"type":29},"2024-10-14",{"date":33,"type":19},"2027-03-15",{"name":35,"class":36},"Mayo Clinic","OTHER",1,{"id":39,"slug":4,"hasResults":10,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":5},"100609328","NCT07213154","Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions","Assessment of Novel Label-free Optical Imaging Technology for the Evaluation of Skin Lesions","Inclusion Criteria:\n\n* Male or Female\n* Candidate with skin lesions\n* Signed study-specific informed consent prior to study entry\n* ≥ 18 years old\n\nExclusion Criteria:\n\n* Prior surgery or radiotherapy to the area to be treated",{"count":45,"type":19},10,"INTERVENTIONAL",[48],"NA","This clinical trial studies how well an optical imaging scan called quantitative oblique back-illumination microscopy (qOBM) helps in diagnosing skin cancer in patients with skin lesions. qOBM is a non-invasive procedure that uses red light for illumination, and may work better than no imaging procedures in aiding doctors in diagnosing skin lesions.",[23,51,52],"Skin Disorder","Skin Neoplasm","2025-12-11",{"date":55,"type":29},"2025-12-16",{"date":57,"type":29},"2025-10-15",{"date":59,"type":19},"2027-09-17",{"name":61,"class":36},"Emory University",""]